Summary
The phase I study of a new anthracycline, 4′-o-tetrahydropyranyl adriamycin, was performed. A dose limiting factor was leukopenia while thrombocytopenia was less frequent and a maximum tolerated dose was determined as 54 mg/m2. Mild gastrointestinal toxicities including anorexia, nausea and vomiting occurred in about half of the patients, while very minimal alopecia was seen in only one patient. A recommended dose for phase II study was established: 40 mg/m2 at 3-week intervals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T: Tetrahydrophyranyl derivatives of daunomycin and adriamycin. J Antibiot 42:1082–1084, 1979
Tsuruo T: Antitumor activity of a tetrahydophyranyl derivative of adriamycin (in Japanese). Can to Kagakuryoho 8:179–180, 1981
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: 4′-o-Tetrahydropyranyl adriamycin as a potential new antitumor agent. Cancer Res 42:1462–1467, 1982
Dantchev D, Paintrand M, Hayat M, Bourut C, Mathé G: Low heart and skin toxicity of a tetrahydrophyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot 32:1085–1086, 1979
Blum RH, Carter SK: Adriamycin, a new anticancer drug with significant clinical activity. Ann Int Med 80:249–259, 1974
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ogawa, M., Miyamoto, H., Inigaki, J. et al. Phase I clinical trial of a new anthracycline: 4′-o-tetrahydropyranyl adriamycin. Invest New Drugs 1, 169–172 (1983). https://doi.org/10.1007/BF00172076
Issue Date:
DOI: https://doi.org/10.1007/BF00172076